恩赛集团
✦ 量化合理价值 计算方式说明
- 基于该股自身过去5年平均市盈率乘以滚动每股收益,推算出的合理价值区间为133.40-190.43。
- 当前价格比按平均倍数计算的合理价值(161.91)高9.1%。
估值 各估值倍数与自身5年区间的对比
同业对比 Medical Care Facilities
| 公司 | 市值 | 市盈率(TTM)i | 市净率i | 股息率i |
|---|---|---|---|---|
| 恩赛集团 (ENSG) | 10.29B | 27.68 | 4.22 | 0.15% |
| HCA Healthcare (HCA) | 99.34B | 15.39 | -14.96 | 0.65% |
| Tenet Healthcare (THC) | 21.52B | 10.33 | 4.62 | 0.00% |
| Encompass Health (EHC) | 12.61B | 20.83 | 4.86 | 0.59% |
| DaVita (DVA) | 11.95B | 15.44 | -15.62 | 0.00% |
| Fresenius Medical Care (FMS) | 11.80B | 11.90 | 0.84 | 3.85% |
StockVane 追踪范围内同行业的其他公司。
Morningstar
当前股价低于晨星合理价值估算4.8%。
合理价值
Ensign Group Inc earns a 3-star quantitative star rating, illustrating our stance that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 7% discount to our quantitative fair value estimate of $185.09 per share; however, some caution is warranted due to this estimate's medium uncertainty rating.
The firm's solid growth increases our estimated fair value. Consistent revenue and earnings growth indicates a company's potential for increased market share and profitability. For example, the firm's revenue 3-year growth of 16.1% sits in the top 30% globally. Robust trailing three-year revenue growth portends a favorable future trajectory, which contributes to our view that shares are undervalued.
Alternatively, the firm's valuation metrics are potentially concerning. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. The firm's book value yield of 24.4%, for example, lies in the bottom 30% compared with global peers. The market value of this company's shares looks expensive relative to the book (accounting) value of equity, which, despite our favorable price/fair value ratio, is a negative attribute.
In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance bodes well for future returns in light of other contributors to our model.
经济护城河
The company's narrow quantitative moat rating indicates it could outearn its cost of capital and maintain robust margins for 10 years or longer. In addition, the company's moderate financial health score is decent and doesn't seriously concern us with regard to financial distress.
作者:Quantitative Equity Report
报价时间 2026-10-16 19:30:05 · 仅供参考,不构成投资建议,也未考虑您的具体情况。
恩赛集团 讨论区 0 条评论